Secondary Pharmacodynamic Studies and In Vitro Pharmacological Profiling

Preclinical Development Handbook: Toxicology

Volumn , Issue , 2007, Pages 581-609

  Armstrong, Duncan ^a   Migeon, Jacques ^b   Rolf, Michael G ^a   Bowes, Joanne ^a   Crawford, Mark ^b   Valentin, Jean Pierre ^a  

^a ASTRAZENECA   (United Kingdom)

^b Cerep   (United States)

Author keywords

Absorption, distribution, metabolism, and excretion (ADME) assays; Common Technical Document (CTD); Reverse sequential approach

Indexed keywords

EID: 84889458207     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249055.ch17     Document Type: Chapter

References (53)

1. Anon. ICH S7A: Note for Guidance on Safety Pharmacology Studies for Human Pharmaceuticals. CPMP/ICH/539/00. 2000.
2. Anon. Guidelines for General Pharmacology Studies - Japanese Guidelines for Non-clinical Studies of Drugs Manual. Tokyo, Japan: Nippo Yakuji; 1995, pp 71-80, pp 125-129.
3. Kinter LB, Valentin JP. Safety pharmacology and risk assessment. Fundam Clin Pharmacol 2002; 16: 175-182.
4. Redfern WS, Wakefield ID, Prior H, Hammond TG, Valentin JP. Safety pharmacology - a progressive approach. Fundam Clin Pharmacol 2002; 16: 161-173.
5. Bass AS, Kinter LB, Williams P. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods 2004; 49: 145-151.
6. Kinter LB, Gossett KA, Kerns WD. Status of safety pharmacology in the pharmaceutical industry - 1993. Drug Dev Res 1994; 32: 208-216.
7. Bass AS, Williams PD. Status of international regulatory guidelines on safety pharmacology. In Williams PD, Bass AS, Eds. Safety Pharmacology A Practical Guide. TherImmune Research Corporation, USA; 2003, pp 9-20.
8. Anon. ICH M3: Timing of Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. CPMP/ICH/286/95. 1997.
9. Anon. ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. CPMP/ICH/302/95. 1997.
10. Anon. The GLP Pocket Book: The Good Laboratory Practice Regulations 1999 and Guide to UK GLP Regulations. London: MCA Publications; 1999, pp 1-75.
11. Anon. ICH S7B: The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. CPMP/ICH/423/02. 2005.
12. Anon. Committee for Proprietary Medicinal Products. Points to Consider: The Assessment of QT Interval Prolongation by Non-cardiovascular Medicinal Products. CPMP/986/96. 1997.
13. Anon. Draft Guideline on the Non-clinical Investigation of the Dependence Potential of Medicinal Products. EMEA/CHMP/SWP/94227/2004. 2005.
14. Anon. ICH M4: Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use. CPMP/ICH/2887/99 rev.2. 1999.
15. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151.
16. Kola I, Rafferty M. Oral communication: new technologies that may impact drug discovery in the 5-10 year time frame workshop. Presented at Biomed Expo, Ann Arbor, Michigan, USA, 2002. Data derived from Prous Science, Drug News Prospect.
17. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenetics J 2006; 6: 16-21.
18. Mangoni AA. Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic, and therapeutic considerations. Drugs Aging 2005; 22: 913-941.
19. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: β-adrenergic receptors - alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Practice Cardiovasc Med 2005; 2: 475-483.
20. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711.
21. Bridgland-Taylor MH, Hargreaves AC, Easter A, Orme A, Henthorn DC, Ding M, Davis AM, Small BG, Heapy CG, Abi-Gerges N, Persson F, Jacobson I, Sullivan M, Albertson N, Hammond TG, Sullivan E, Valentin JP, Pollard CE. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J Pharmacol Toxicol Methods 2006; 54: 189-199.
22. Fliri AF, Loging WT, Thadeio PF, Volkmann RA. Biological spectra analysis: linking biological activity profiles to molecular structure. Proc Nat Acad Sci USA 2005; 102: 261-266.
23. Fliri AF, Loging WT, Thadeio PF, Volkmann RA. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol 2005; 1: 389-391.
24. Maemoto T, Finlayson K, Olverman HJ, Akahane A, Horton RW, Butcher SP. Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists. Br J Pharmacol 1997; 122: 1202-1208.
25. Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 2005; 10: 1421-1433.
26. Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, Barbosa F, Migeon JC. Predicting ADME properties and side effects: the BioPrint approach. Curr Opin Drug Discov Dev 2003; 6: 470-480.
27. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 17: S52-S60.
28. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism- based inhibition of cytochrome P-450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44: 279-304.
29. Siddiqui MAA, Keam SJ. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs 2006; 66: 693-710.
30. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? J Electrocardiol 2004; 37 (Suppl): 15-24.
31. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsades de pointes. Trends Pharmacol Sci 2003; 24: 619-625.
32. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel anti-anginal agent with anti-arrhythmic properties. Circulation 2004; 110: 904-910.
33. Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmut AC, Burashnikov A, Diego JM, Fish JM, Cordeiro JM, Goodrow RJ Jr, Scornik F, Perez G. Electrophysiologic properties and anti-arrhythmic actions of a novel anti-anginal agent. J Cardiovasc Pharmacol Ther 2004; 9 (Suppl 1): S65-S83.
34. Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004; 142: 1300-1308.
35. Song Y, Skrycok JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pre- arrhythmic effects of increasing late I Na in guinea-pig ventricular myocytes. J Cardiovasc Pharmacol 2004; 44: 192-199.
36. Jackson PC. Innervation of the iris by individual parasympathetic axons in the adult mouse. J Physiol 1986; 378: 485-495.
37. Gupta N, Drance SM, McAllister R, Prasad S, Rootman J, Cynader MS. Localization of M 3 muscarinic receptor subtype and mRNA in the human eye. Ophthalmic Res 1994; 26: 207-123.
38. Lin S, Kajimura M, Takeuchi K, Kodaira M, Hanai H, Kaneko E. Expression of muscarinic receptor subtypes (effect of M3 selective antagonist on gastric motility and in rat gastric smooth muscle emptying). Dig Dis Sci 1997; 42: 907-914.
39. Ross WA. Premedication for upper gastrointestinal endoscopy. Gastrointest Endosc 1989; 32: 120-126.
40. Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Practice 2006; 60: 119-126.
41. Carley DW. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I. IDrugs 2005; 8: 306-309.
42. Carley DW. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part II. IDrugs 2005; 8: 310-313.
43. Bradley D. Why big pharma needs to learn the three " R"s. Nat Rev Drug Discov 2005; 4: 446.
44. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3: 673-683.
45. Winter C, Flataker L. The effect of anti-histaminic drugs on the performance of trained rats. J Pharmacol Exp Ther 1951; 101: 156-162.
46. Courvoisier S. Pharmacodynamic basis for the use of chlorpromazine in psychiatry. J Clin Exp Psychopathol 1956; 17: 25-37.
47. Domino EF. History of modern psychopharmacology: a personal view with an emphasis on anti-depressants. Psychosom Med 1999; 61: 591-598.
48. Laborit H, Huguenard P. L'hibernation artificielle par MoyEnes pharmacodynamiques et physiques En chirurgie. J Chir 1951; 67: 631-641.
49. Laborit H, Huguenard P. L'hibernation artificielle par moyenes pharmacodynamiques et physiques. La Presse Med 1951; 59: 13-29.
50. Laborit H, Huguenard P, Alluaume R. Un nouveau stabilisateur vegetatif (le 4560 RP). La Presse Med 1952; 60: 206-208.
51. Delay J, Deniker P. Le traitement des psychoses par une methode neurolytque derive de l'hibernotherapie (Le 4560 R.P. utilise seul. En cure prolongee et continue.) CR Congress Med Alien Neruol France 1952; 50: 497-502.
52. Deniker P. Introduction of neuroleptic chemotherapy into psychiatry. In Ayd FJ, Blackwell B, Eds. Discoveries in Biological Psychiatry. Philadelphia: Lippincott; 1970, pp 155-164.
53. Carlsson A, Lindquist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-144.